Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals4.75%+4.74 ppHealth Care Equipment3.24%+3.24 ppBiotechnology2.55%+2.55 ppLife Sciences Tools & Services2.21%+2.20 ppManaged Health Care1.98%+1.98 ppHealth Care Services0.83%+0.83 ppHealth Care Supplies0.31%+0.31 ppHealth Care Distributors0.29%+0.29 ppHealth Care Facilities0.28%+0.28 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.55%
Industry change · 12M
+2.55 pp
Biotechnology · contribution
+2.548 pp
Company participation
100%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Jul 2021 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $205.4bn | 0.704% | -0.009 pp | +0.704 pp | +28.6% | Yes |
| Moderna → MRNA | United States | $142.0bn | 0.487% | +0.487 pp | +0.487 pp | +377.2% | Yes |
| Amgen → AMGN | United States | $138.8bn | 0.476% | -0.023 pp | +0.475 pp | +1.5% | Yes |
| Gilead Sciences → GILD | United States | $85.6bn | 0.294% | +0.005 pp | +0.293 pp | +2.6% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $54.0bn | 0.185% | +0.021 pp | +0.185 pp | -9.1% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $52.3bn | 0.179% | -0.025 pp | +0.179 pp | -25.9% | Yes |
| Biogen → BIIB | United States | $48.7bn | 0.167% | +0.021 pp | +0.167 pp | +18.9% | Yes |
| Incyte → INCY | United States | $17.0bn | 0.058% | -0.010 pp | +0.058 pp | -21.7% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.